139 related articles for article (PubMed ID: 29097308)
1. Analysis of natural product regulation of opioid receptors in the treatment of human disease.
Badal S; Turfus S; Rajnarayanan R; Wilson-Clarke C; Sandiford SL
Pharmacol Ther; 2018 Apr; 184():51-80. PubMed ID: 29097308
[TBL] [Abstract][Full Text] [Related]
2. A Survey of Molecular Imaging of Opioid Receptors.
Cumming P; Marton J; Lilius TO; Olberg DE; Rominger A
Molecules; 2019 Nov; 24(22):. PubMed ID: 31752279
[TBL] [Abstract][Full Text] [Related]
3. Opioid Receptors.
Stein C
Annu Rev Med; 2016; 67():433-51. PubMed ID: 26332001
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.
Livingston KE; Traynor JR
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18369-74. PubMed ID: 25489080
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
6. Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen.
Burford NT; Wehrman T; Bassoni D; O'Connell J; Banks M; Zhang L; Alt A
J Biomol Screen; 2014 Oct; 19(9):1255-65. PubMed ID: 25047277
[TBL] [Abstract][Full Text] [Related]
7. Untangling the complexity of opioid receptor function.
Valentino RJ; Volkow ND
Neuropsychopharmacology; 2018 Dec; 43(13):2514-2520. PubMed ID: 30250308
[TBL] [Abstract][Full Text] [Related]
8. Evidence from basic research for opioid combinations.
Davis MP
Expert Opin Drug Discov; 2012 Feb; 7(2):165-78. PubMed ID: 22468917
[TBL] [Abstract][Full Text] [Related]
9. Endogenous opiates and behavior: 2014.
Bodnar RJ
Peptides; 2016 Jan; 75():18-70. PubMed ID: 26551874
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
11. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.
Bowdle TA
Drug Saf; 1998 Sep; 19(3):173-89. PubMed ID: 9747665
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist-antagonist drugs in acute and chronic pain states.
Hoskin PJ; Hanks GW
Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
[TBL] [Abstract][Full Text] [Related]
14. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
15. Duration of opioid receptor blockade determines biotherapeutic response.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
[TBL] [Abstract][Full Text] [Related]
16. Tuning Down the Pain - An Overview of Allosteric Modulation of Opioid Receptors: Mechanisms of Modulation, Allosteric Sites, Modulator Syntheses.
Bartuzi D; Wróbel TM; Kaczor AA; Matosiuk D
Curr Top Med Chem; 2020; 20(31):2852-2865. PubMed ID: 32479245
[TBL] [Abstract][Full Text] [Related]
17. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
[TBL] [Abstract][Full Text] [Related]
18. [Development of opioid tolerance -- molecular mechanisms and clinical consequences].
Freye E; Latasch L
Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Jan; 38(1):14-26. PubMed ID: 12522725
[TBL] [Abstract][Full Text] [Related]
19. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.
Rozenfeld R; Devi LA
FASEB J; 2007 Aug; 21(10):2455-65. PubMed ID: 17384143
[TBL] [Abstract][Full Text] [Related]
20. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
